2005
Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study
Modi W, Scott K, Goedert J, Vlahov D, Buchbinder S, Detels R, Donfield S, O'Brien S, Winkler C. Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study. Genes & Immunity 2005, 6: 691-698. PMID: 16177829, DOI: 10.1038/sj.gene.6364258.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAllelesBlack or African AmericanChemokine CXCL12Chemokines, CXCChildCohort StudiesDisease ProgressionFemaleGene FrequencyHaplotypesHIV InfectionsHIV-1HumansLongitudinal StudiesMaleOdds RatioPolymorphism, Single NucleotideRisk FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsSDF-1 geneCohort studySingle nucleotide polymorphismsAfrican AmericansOnly natural ligandSingle disease outcomesX4 HIV-1HIV-1 infectionAIDS Cohort StudyRisk of infectionMACS cohortDisease outcomeHIV-1Epidemiological studiesSDF-1Significant associationChemokine genesInfectionRs1801157Natural ligandProgressionHaplotype analysisCommon haplotypeCXCR4CohortSexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
Rusch M, Farzadegan H, Tarwater P, Safaeian M, Vlahov D, Strathdee S. Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy. AIDS And Behavior 2005, 9: 289-299. PMID: 16133905, DOI: 10.1007/s10461-005-9003-4.Peer-Reviewed Original ResearchConceptsInjection drug usersCondom useAntiretroviral therapyHIV testingDrug usersEligible injection drug usersRisk behaviorsActive antiretroviral therapyInconsistent condom useSexual risk behaviorsIDU cohortHIV transmissionRetrospective analysisLower riskStudy exposureSexual riskLong-term studiesTherapySignificant changesCounselingRiskExposureLogistic modelWidespread availabilityCohort
2003
Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants. American Journal Of Epidemiology 2003, 158: 695-704. PMID: 14507606, DOI: 10.1093/aje/kwg209.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug injection behaviorDrug usersIntravenous Experience (ALIVE) studyDrug treatment programsHistory of incarcerationLogistic regression modelsALIVE studySemiannual visitsMultinomial logistic regression modelsBaseline factorsChronic diseasesDrug injectionRecent overdoseCessation attemptsDrug use transitionsDrug injectorsCommunity outreach effortsLongitudinal patternsHigh mortalityEarly determinantsYounger ageTreatment programInjection behaviorStudy periodThe Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland
Juday T, Wu A, Celentano D, Rick K, Wang M, Vlahov D. The Role of Medicaid HMO Enrollment in the Longitudinal Utilization of Medical Care Services in a Cohort of Injecting Drug users in Baltimore, Maryland. Substance Use & Addiction Journal 2003, 24: 27-41. PMID: 12652093, DOI: 10.1080/08897070309511531.Peer-Reviewed Original ResearchConceptsAmbulatory care visitsCare visitsInpatient admissionsHMO enrollmentDrug usersMedicaid HMO enrolleesMore inpatient admissionsInjecting Drug UsersMedical care utilizationNatural history studiesIntravenous Experience (ALIVE) studyMedical care servicesCommunity-based sampleLongitudinal utilizationER visitsHIV infectionCare utilizationMedicaid beneficiariesHMO enrolleesCare servicesIDUsInappropriate utilizationUtilization differencesMedicaidMedicaid HMOs
2001
Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users
Vlahov D, Safaien M, Lai S, Strathdee S, Johnson L, Sterling T, Celentano D. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001, 15: 2311-2316. PMID: 11698705, DOI: 10.1097/00002030-200111230-00013.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seropositive injection drug usersActive antiretroviral therapyUntreated groupHigh-risk behaviorsAntiretroviral therapyConsecutive visitsDrug usersRisk behaviorsInitiation of HAARTCD4 cell countOngoing prospective studySemi-annual interviewsLinear growth curve analysesHAART useMedian ageMedication useProspective studyNeedle sharingHAARTCell countUnprotected sexRisk-related behaviorsCurve analysisStudy periodHealth care utilization among young adult injection drug users in Harlem, New York
Cronquist A, Edwards V, Galea S, Latka M, Vlahov D. Health care utilization among young adult injection drug users in Harlem, New York. Journal Of Substance Abuse 2001, 13: 17-27. PMID: 11547618, DOI: 10.1016/s0899-3289(01)00073-6.Peer-Reviewed Original ResearchConceptsYoung adult injection drug usersAdult injection drug usersInjection drug usersNeedle exchange programsHealth care utilizationCare utilizationHealth careDrug treatmentDrug usersHealth insuranceMedical careYoung injection drug usersCross-sectional studyHealth insurance coverageNEP usersUse of servicesDrug useHealth servicesAge 18Logistic regressionHealth conditionsCareInsurance coverageMonthsTreatmentImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. PMID: 11317071, DOI: 10.1097/00126334-200104010-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBaltimoreBody Mass IndexCD4 Lymphocyte CountChronic DiseaseFemaleHemoglobinsHIV InfectionsHIV-1HumansLongitudinal StudiesMaleMultivariate AnalysisPrevalenceSex FactorsSubstance Abuse, IntravenousViral LoadConceptsInjection drug usersPlasma HIV loadActive antiretroviral therapyAntiretroviral therapyHIV loadOpportunistic infectionsCopies/Mean decreaseDrug usersHIV-positive injection drug usersPotent antiretroviral therapyImprovement of anemiaBody mass indexIncrease of hemoglobinAntiretroviral medicationsHIV infectionMass indexControl subjectsOverall prevalenceChronic diseasesAnemiaNutritional statusMean increaseMultivariate analysisHAARTMortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study
Ickovics J, Hamburger M, Vlahov D, Schoenbaum E, Schuman P, Boland R, Moore J, Group F. Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study. JAMA 2001, 285: 1466-1474. PMID: 11255423, DOI: 10.1001/jama.285.11.1466.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusChronic depressive symptomsCD4 cell countHIV-seropositive womenTreatment of depressionDepressive symptomsCell countDisease progressionBaseline CD4 cell countCD4 cell count declineHIV Epidemiologic Research StudyCell count declineCD4 lymphocyte countBaseline viral loadEpidemiologic Studies Depression ScaleHIV disease progressionHIV Epidemiology Research StudyLongitudinal cohort studyEpidemiologic research studiesImpact of depressionAcademic medical centerSelf-reported CenterCohort studyLymphocyte countCount declineInitial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
The prevalence of homelessness among injection drug users with and without HIV infection
Song J, Safaeian M, Strathdee S, Vlahov D, Celentano D. The prevalence of homelessness among injection drug users with and without HIV infection. Journal Of Urban Health 2000, 77: 678-687. PMID: 11194310, PMCID: PMC3456762, DOI: 10.1007/bf02344031.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusInjection drug usersInjection drug useIndependent predictorsDrug usersDrug useActive injection drug useLongitudinal cohort studyCross-sectional studyHIV/AIDSCross-sectional investigationHIV seroconversionCohort studyHIV seroprevalenceHIV infectionPrevalence of homelessnessImmunodeficiency virusMale sexLogistic regressionPrevalenceParticipantsMore experiencePredictorsSeroconversionSerostatusCervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women
Ahdieh L, Munoz A, Vlahov D, Trimble C, Timpson L, Shah K. Cervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women. American Journal Of Epidemiology 2000, 151: 1148-1157. PMID: 10905527, DOI: 10.1093/oxfordjournals.aje.a010165.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansImmunosuppression TherapyIncidenceLongitudinal StudiesPapillomaviridaePapillomavirus InfectionsRisk AssessmentSurvival AnalysisTumor Virus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsConceptsCervical intraepithelial neoplasiaHuman papillomavirus infectionHPV positivityHPV clearancePapillomavirus infectionHIV infectionBiopsy-confirmed cervical intraepithelial neoplasiaAssociation of HIVPotent antiretroviral therapyCervicovaginal lavage specimensHuman immunodeficiency virusCells/Reversal of immunosuppressionPolymerase chain reaction-based assaySeronegative womenAntiretroviral therapyHIV- womenHPV resultsHIV- participantsHPV DNACervical neoplasiaHIV serostatusIntraepithelial neoplasiaImmunodeficiency virusRelated immunosuppressionImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00042560-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug useImproved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy.
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-6. PMID: 10836754, DOI: 10.1097/00126334-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsSerum alpha-tocopherol levelsAlpha-tocopherolPotent antiretroviral therapyAlpha-tocopherol levelsExcess oxidative stressOxidative stress levelsAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceDrug useHIV
1999
Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load
Lyles C, Dorrucci M, Vlahov D, Pezzotti P, Angarano G, Sinicco A, Alberici F, Alcorn T, Vella S, Rezza G. Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. The Journal Of Infectious Diseases 1999, 180: 1018-1024. PMID: 10479126, DOI: 10.1086/314980.Peer-Reviewed Original ResearchConceptsHIV-1 loadVirus loadHuman immunodeficiency virus type 1 (HIV-1) loadHuman immunodeficiency virus type 1 (HIV-1) seroconvertersCD4 cells/microL.Low CD4 cell countsItalian Seroconversion StudyCD4 cell countCells/microL.Injection drug useCourse of diseaseReverse transcriptase-polymerase chain reactionHigh virus loadTranscriptase-polymerase chain reactionClinical AIDSMale sexProspective studyDisease progressionSeroconversion StudyCell countDrug useSustained increaseSeroconversionAIDSFrozen serumSex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling T, Lyles C, Vlahov D, Astemborski J, Margolick J, Quinn T. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. The Journal Of Infectious Diseases 1999, 180: 666-672. PMID: 10438353, DOI: 10.1086/314967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 RNA levelsHIV-1 seroconvertersSex differencesCopies/mLHIV-1 pathogenesisInjection drug usersCase-control studyTime of seroconversionCross-sectional studyCourse of infectionMale patientsRapid progressorsFemale patientsCopies/Drug usersMale controlsVirus levelsPatientsRNA levelsSeroconvertersWomenMenNonprogressorsSeroconversionProgressorsComparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure
Kimura M, Converse P, Astemborski J, Rothel J, Vlahov D, Comstock G, Graham N, Chaisson R, Bishai W. Comparison between a Whole Blood Interferon-γ Release Assay and Tuberculin Skin Testing for the Detection of Tuberculosis Infection among Patients at Risk for Tuberculosis Exposure. The Journal Of Infectious Diseases 1999, 179: 1297-1300. PMID: 10191241, DOI: 10.1086/314707.Peer-Reviewed Original ResearchConceptsTuberculin skin testIFN-gamma releaseTuberculosis infectionWhole-Blood Interferon-γ Release AssayStandard tuberculin skin testInterferon-γ release assaysPercent agreementCulture-confirmed tuberculosisHIV-seropositive subjectsTuberculin skin testingHuman immunodeficiency virusInterferon-gamma releaseIntravenous drug usersSingle blood drawSeronegative patientsTuberculosis exposureSkin testingUninfected personsImmunodeficiency virusSkin testBlood drawUrban BaltimoreDrug usersRelease assaysFurther evaluationPersistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection
Villano S, Vlahov D, Nelson K, Cohn S, Thomas D. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999, 29: 908-914. PMID: 10051497, DOI: 10.1002/hep.510290311.Peer-Reviewed Original ResearchConceptsRecombinant immunoblot assayHCV RNAAcute infectionViral clearanceAcute hepatitis C virus (HCV) infectionAcute hepatitis C infectionHepatitis C virus infectionPersistence of viremiaAcute HCV infectionAcute hepatitis CC virus infectionHepatitis C infectionTime of seroconversionPeak viral titersHealth care providersSingle laboratory testIllicit drug useHCV seroconversionC infectionHCV infectionHepatitis CPersistent viremiaClinical featuresHCV subtypesPolymerase chain reaction
1998
Sex differences in HIV-1 viral load and progression to AIDS
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, Quinn T, Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1998, 352: 1510-1514. PMID: 9820299, DOI: 10.1016/s0140-6736(98)02372-1.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell countProportional hazards modelBranched-chain DNAViral loadQuantitative microcultureReverse transcriptase-PCRPlasma HIV-1 RNA measurementsCell countHIV-1 RNA measurementsUnivariate proportional hazard modelHIV-1 viral loadSame viral loadViral load associationsVisit 3 yearsHIV-1 loadViral load measurementsAntiretroviral therapyAntiretroviral treatmentBaseline visitCommunity clinicsObservational studyHIV-1Current recommendationsHigh riskSocially desirable response tendency as a correlate of accuracy of self‐reported HIV serostatus for HIV seropositive injection drug users
Latkin C, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self‐reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998, 93: 1191-1197. PMID: 9813900, DOI: 10.1046/j.1360-0443.1998.93811917.x.Peer-Reviewed Original ResearchConceptsSelf-reported HIV serostatusSocial desirabilityInjection drug usersCorrelates of accuracyDesirable response tendenciesHIV serostatusDrug usersResponse tendenciesDesirable respondingHIV-seronegative participantsALIVE studyPredictive validityHIV-seropositive injection drug usersActive injection drug usersLongitudinal studySeropositive injection drug usersPositive predictive value 97Higher scoresHIV-seropositive participantsHIV prevention studyQuestionable validityNegative predictive valueParticipantsSeronegative participantsSeropositive participants
1997
Syphilis Serology in Human Immunodeficiency Virus Infection: Evidence for False-Negative Fluorescent Treponemal Testing
Erbelding E, Vlahov D, Nelson K, Rompalo A, Cohn S, Sanchez P, Quinn T, Brathwaite W, Thomas D. Syphilis Serology in Human Immunodeficiency Virus Infection: Evidence for False-Negative Fluorescent Treponemal Testing. The Journal Of Infectious Diseases 1997, 176: 1397-1400. PMID: 9359747, DOI: 10.1086/517330.Peer-Reviewed Original ResearchConceptsFTA-ABS testHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionBFP reactionsVirus infectionRapid plasma reagin titerFluorescent treponemal antibody absorption testInjection drug usersAntibody absorption testPresence of antibodiesTreponema pallidum antigensFalse positive reactorsBFP reactorsSyphilis serologySerologic patternTreatment historyDrug usersMembrane antigenTreponemal testingAntigenNegative resultsSyphilisInfectionAntibodiesSerology